In the YMDD variant group lymphocyte subsets had no statistically significant change.
而变异组患者的淋巴细胞亚群则无显著改变。
The shorter time YMDD variant takes to become wild strain, the worse the prognosis will be.
YMDD变异株转变为野生株的时间越短，其预后可能越差。
Conclusions During lamivudine therapy, there is no relation between the YMDD mutation and the HBV genotypes.
结论拉米夫定治疗期间，HBV的YMDD变异不受病毒基因型的影响。
Objective:To observe the efficacy and safety of adefovir dipivoxil(ADV)for chronic hepatitis B(CHB)with YMDD mutation during lamivudine(LAM)therapy.
目的 系统评价与拉米夫定相关的乙型肝炎病毒YMDD区变异后不同抗病毒治疗方法的疗效和安全性。
Results PCR, restriction endonuclease method and direct sequence analysis demonstrated that plasmids of YMDD, YVDD and YIDD were constructed successfully.
结果经pcr方法、酶切鉴定及直接测序鉴定出YMDD、YVDD和YIDD质粒构建成功，且该方法具有较好的敏感性和特异性。
Conclusion the combination detection of YMDD variants, HBV DNA and HBV serum markers may define HBV reinfection after liver transplantation in the patients with hepatitis b.
结论乙型肝炎肝硬化患者肝移植后预防乙型肝炎复发应采用HBVDNA、YMDD变异及血清标志物联合检测。
To set up using the gene chip technology to detect and identify quickly and accurately the HBV P gene YMDD Motif mutation during the chronic hepatitis treated with lamivudine.
建立乙型肝炎病毒变异基因诊断芯片对拉米夫定治疗慢性乙型肝炎过程中出现的肝炎病毒P基因区YMDD变异进行快速准确的检测方法。
Methods Serum samples from 188 chronic hepatitis B patients with lamivudine therapy were collected and quantitatively tested with real-time PCR for HBV DNA and YMDD mutations.
方法将接受拉米夫定治疗的188例患者根据治疗时间进行分组，采用实时荧光PCR方法定量检测各组患者血清HBVDNA水平和酪氨酸-甲硫氨酸-天冬氨酸-天冬氨酸（YMDD）变异。
To guide reasonably antival therapy in clinic and make therapic remedy, it is necessary for HBV-infected patients before or after antiviral therapy to detect HBV YMDD mutations.
HBV感染患者在治疗前后有必要检测是否存在HBV YMDD 变异株感染，为指导临床科学合理用药和制定治疗方案提供依据。
Conclusion it would be helpful to adjust the therapeutic regimen by testing YMDD mutations in patients who receive lamivudine therapy more than 6 months without complete virologic response.
结论对拉米夫定治疗6个月以上而没有达到病毒学完全应答的患者进行YMDD变异检测，有助于及时调整治疗方案。
Conclusion it would be helpful to adjust the therapeutic regimen by testing YMDD mutations in patients who receive lamivudine therapy more than 6 months without complete virologic response.
结论对拉米夫定治疗6个月以上而没有达到病毒学完全应答的患者进行YMDD变异检测，有助于及时调整治疗方案。
应用推荐